ロード中...
Genetic polymorphism of the inhibitory IgG Fc receptor FcγRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab
Polymorphisms of activating FcγRIIIa (CD16) and FcγRIIa (CD32a) have been found to predict rituximab response, probably because of the relative efficiency of different FcγR variants in performing antibody-dependent cellular cytotoxicity. The inhibitory FcγRIIb (CD32b) has an opposing effect on effec...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2910394/ https://ncbi.nlm.nih.gov/pubmed/19452316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190902829441 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|